<?xml version='1.0' encoding='utf-8'?>
<?xml-stylesheet type="text/xsl" href="/v2/static/oai2.xsl"?>
<OAI-PMH xmlns="http://www.openarchives.org/OAI/2.0/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/ http://www.openarchives.org/OAI/2.0/OAI-PMH.xsd">
  <responseDate>2026-10-10T06:28:14Z</responseDate>
  <request identifier="oai:figshare.com:article/28646573" metadataPrefix="oai_dc" verb="GetRecord">https://api.figshare.com/v2/oai</request>
  <GetRecord>
    <record>
      <header>
        <identifier>oai:figshare.com:article/28646573</identifier>
        <datestamp>2026-09-14T08:09:24Z</datestamp>
        <setSpec>category_24778</setSpec>
        <setSpec>item_type_3</setSpec>
        <setSpec>month_year_09_2026</setSpec>
      </header>
      <metadata>
        <oai_dc:dc xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"  xmlns:oai_dc="http://www.openarchives.org/OAI/2.0/oai_dc/" xmlns:dc="http://purl.org/dc/elements/1.1/" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/oai_dc/ http://www.openarchives.org/OAI/2.0/oai_dc.xsd">
          <dc:title>&lt;sub&gt;Datasets for the eLife manuscript"&lt;/sub&gt;&lt;sub&gt;ORMDL3 restrains type I interferon signaling and anti-tumor immunity by promoting RIG-I degradation"&lt;/sub&gt;</dc:title>
          <dc:creator>Qi Zeng (20922783)</dc:creator>
          <dc:creator>Chen Yao (137375)</dc:creator>
          <dc:creator>Shimeng Zhang (20922826)</dc:creator>
          <dc:creator>Yizhi Mao (20922829)</dc:creator>
          <dc:creator>Jing Wang (20922832)</dc:creator>
          <dc:creator>Ziyang Wang (17796838)</dc:creator>
          <dc:creator>Chunjie Sheng (20922834)</dc:creator>
          <dc:creator>Shuai Chen (20922839)</dc:creator>
          <dc:subject>Cancer cell biology</dc:subject>
          <dc:subject>ORMDL3</dc:subject>
          <dc:subject>RIG-I-like receptors signaling</dc:subject>
          <dc:description>&lt;p dir="ltr"&gt;Mounting evidence has demonstrated the genetic association of ORMDL sphingolipid biosynthesis regulator 3 (ORMDL3) gene polymorphisms with bronchial asthma and a diverse set of inflammatory disorders. However, its role in type I interferon (type I IFN) signaling remains poorly defined. Herein, we report that ORMDL3 is a negative modulator of the type I IFN signaling by interacting with mitochondrial antiviral signaling protein (MAVS) and subsequently promoting the proteasome-mediated degradation of retinoic acid-inducible gene I (RIG-I). Immunoprecipitation coupled with mass spectrometry (IP-MS) assays uncovered that ORMDL3 binds to ubiquitin-specific protease 10 (USP10), which forms a complex with and stabilizes RIG-I through decreasing its K48- linked ubiquitination. ORMDL3 thus disrupts the interaction between USP10 and RIG-I, thereby promoting RIG-I degradation. Additionally, subcutaneous syngeneic tumor models in C57BL/6 mice revealed that inhibition of ORMDL3 enhances anti-tumor efficacy by augmenting the proportion of cytotoxic CD8 positive T cells and IFN production in the tumor microenvironment (TME). Collectively, our findings reveal the pivotal roles of ORMDL3 in maintaining antiviral innate immune responses and anti-tumor immunity.&lt;/p&gt;</dc:description>
          <dc:date>2025-03-24T02:39:13Z</dc:date>
          <dc:type>Dataset</dc:type>
          <dc:type>Dataset</dc:type>
          <dc:identifier>10.6084/m9.figshare.28646573.v3</dc:identifier>
          <dc:relation>https://figshare.com/articles/dataset/_sub_Datasets_for_the_eLife_manuscript_sub_sub_ORMDL3_restrains_type_I_interferon_signaling_and_anti-tumor_immunity_by_promoting_RIG-I_degradation_sub_/28646573</dc:relation>
          <dc:rights>CC BY 4.0</dc:rights>
        </oai_dc:dc>
      </metadata>
    </record>
  </GetRecord>
</OAI-PMH>
